CN1698607A - Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof - Google Patents
Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof Download PDFInfo
- Publication number
- CN1698607A CN1698607A CN 200410038987 CN200410038987A CN1698607A CN 1698607 A CN1698607 A CN 1698607A CN 200410038987 CN200410038987 CN 200410038987 CN 200410038987 A CN200410038987 A CN 200410038987A CN 1698607 A CN1698607 A CN 1698607A
- Authority
- CN
- China
- Prior art keywords
- oral cavity
- disintegration tablet
- cavity disintegration
- tablet according
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims abstract description 21
- 210000000214 mouth Anatomy 0.000 title claims abstract description 19
- 229960005489 paracetamol Drugs 0.000 title claims abstract description 14
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 title claims abstract description 10
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 title claims abstract description 10
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract 3
- 239000003814 drug Substances 0.000 claims description 13
- 235000019640 taste Nutrition 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- 235000012343 cottonseed oil Nutrition 0.000 claims description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 230000000873 masking effect Effects 0.000 claims description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000000835 fiber Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 claims description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 238000005303 weighing Methods 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims 1
- 235000010358 acesulfame potassium Nutrition 0.000 claims 1
- 229960004998 acesulfame potassium Drugs 0.000 claims 1
- 239000000619 acesulfame-K Substances 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 235000019658 bitter taste Nutrition 0.000 claims 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims 1
- 239000004327 boric acid Substances 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 239000001530 fumaric acid Substances 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000741 silica gel Substances 0.000 claims 1
- 229910002027 silica gel Inorganic materials 0.000 claims 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
- 229940013618 stevioside Drugs 0.000 claims 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims 1
- 235000019202 steviosides Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 6
- 201000009240 nasopharyngitis Diseases 0.000 abstract description 5
- 210000003296 saliva Anatomy 0.000 abstract description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 abstract 2
- 208000019505 Deglutition disease Diseases 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000004925 Acrylic resin Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention is related to a compound preparation for treating common cold, i.e. paracetamol pseudoephedrine hydrochloride and chlorphenamine maleate orally disintegrating tablet, and its preparing process, wherein the orally disintegrating tablet is prepared from principal ingredients and several subsidiary materials through the conventional compressing technique, its advantages include no requirement of administration with water, easy administration, quick disintegration in oral cavity when contacting saliva, thus facilitating patients with dysphagia, difficulty of fetching water and busy work, especially suitable for children and the elderly.
Description
Technical field
The present invention relates to a kind of compound medicine novel form of pharmaceutical, particularly treatment common cold or grippal paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral disintegration tablet and preparation method thereof.
Background technology
The commercially available preparation that is used for the treatment of common cold or influenza symptom need be used water delivery service mostly when taking at present, and is usually very inconvenient; The present invention is a kind of novel dosage form, though adopt common sheeting equipment and preparation technology, has certain rigidity, but after putting into the oral cavity and running into saliva is rapid disintegrate, go into the stomach onset with swallowing act, it is very convenient that this can improve under the environment of drug effect (bioavailability), especially old man, child and water intaking inconvenience medication greatly, from and can improve the compliance that the patient takes medicine.Therefore, said preparation has certain market advantage than like product, is with a wide range of applications.
Summary of the invention
The object of the present invention is to provide a kind of oral cavity disintegration tablet that contains multiple active constituents of medicine and preparation method thereof, this sheet adopts common sheeting equipment and easy manufacture technology, have certain rigidity, can satisfy the requirement of production, packing, accumulating, have good mouthfeel simultaneously again.
Technical solution of the present invention is:
A kind of that quick oral cavity disintegration tablet of the pseudo-fiber crops of compound paracetamol for the treatment of and alleviating common cold or influenza symptom is made up of principal agent and adjuvant, wherein:
Acetaminophen: 15%～40%
Pseudoephedrine hydrochloride: 0.1%～10%
Chlorphenamine maleate: 0.01%～5%
Filler: 5%～70%
Disintegrating agent: 1%～15%
Correctives: 1%
Lubricant: 0.5%
The method for preparing that quick oral cavity disintegration tablet of the pseudo-fiber crops of compound compound paracetamol is:
Take by weighing the active constituents of medicine of ormal weight, mix homogeneously is after the adding suitable quantity of water is granulated, with Eudragit E 100 dispersions granule is carried out the taste masking Cotton seeds, obtain the following taste masked particle of 450 μ m, then with above-mentioned all the other adjuvant mix homogeneously, tabletting, packing behind the adding lubricant.
Oral cavity disintegration tablet provided by the invention, each active component content uniformity is better, need not to use water delivery service, disintegrate in 5～50 seconds in the oral cavity, no sand type in the oral cavity, bioavailability is higher, is particularly useful for the patient of infant and child, old people and water intaking inconvenience.
The specific embodiment
Enumerate three embodiment below, the present invention is further specified.
Embodiment 1
With acetaminophen 80g, pseudoephedrine hydrochloride 7.5g, chlorphenamine maleate 0.5g mix homogeneously, after adding the suitable quantity of water granulation, with the strange E100 dispersion of acrylic resin You Te coating, obtain the following taste masked particle 145g of 450 μ m, add mannitol 65g, sorbitol 57g, carboxymethyl starch sodium 20g, aspartame 3g, essence 1g mix homogeneously then, add sodium stearyl fumarate 1.5g again, tabletting behind the mixing, make 1000, every heavy 292.5mg, wherein contain medicine active component coating taste masked particle 145mg, adjuvant 147.5mg.
Embodiment 2
Acetaminophen 160g, pseudoephedrine hydrochloride 15g, chlorphenamine maleate 1g mix homogeneously obtain taste masked particle 264g below the 450 μ m with embodiment 1 method, add StarLac then
90g, mannitol 204g, crospolyvinylpyrrolidone 30g, aspartame 6g, essence 3g mix homogeneously, add tabletting behind the sodium stearyl fumarate 3g mixing again, make 1000, every heavy 600mg, wherein contain medicine active component coating taste masked particle 264mg, adjuvant 336mg.
Embodiment 3
Acetaminophen 160g, pseudoephedrine hydrochloride 15g, chlorphenamine maleate 1g mix homogeneously obtain taste masked particle 264g below the 450 μ m with embodiment 1 method, add MicroceLac then
60g, mannitol 136g, carboxymethyl starch sodium 20g, crospolyvinylpyrrolidone 10g, aspartame 5g, essence 2.5g mix homogeneously, add tabletting behind the sodium stearyl fumarate 2.5g mixing again, make 1000, every heavy 500mg, wherein contain medicine active component coating taste masked particle 264mg, adjuvant 236mg.
More than the disintegration time of three made slice, thin pieces of embodiment be respectively 28 seconds, 40 seconds, 36 seconds; The dissolution in vitro of slightly solubility component acetaminophen (changeing the basket method) data are respectively: 45min stripping 90.6%, 88.5%, 89.9% respectively.
Product of the present invention is mainly used in treatment and alleviates the symptoms such as heating, headache, extremities aching pain, sneeze, rhinorrhea, nasal obstruction, cough and pharyngalgia that common cold or influenza cause.
Claims (10)
1, a kind of that quick oral cavity disintegration tablet of the pseudo-fiber crops of compound paracetamol for the treatment of flu, it is characterized in that it is made up of principal agent and adjuvant, principal agent comprises acetaminophen, pseudoephedrine hydrochloride and three kinds of active constituents of medicine of chlorphenamine maleate, and the percentage by weight proportioning of each component is as follows:
Acetaminophen: 15%～40%
Pseudoephedrine hydrochloride: 0.1%～10%
Chlorphenamine maleate: 0.01%～5%
Filler: 5%～70%
Disintegrating agent: 1%～15%
Correctives: 1%
Lubricant: 0.5%
2, oral cavity disintegration tablet according to claim 1 is characterized in that active constituents of medicine need carry out Cotton seeds to cover bitterness.
3, oral cavity disintegration tablet according to claim 2 carries out the taste masking coating with coating material to granule, increases weight to be particulate 15%～70%.
4, oral cavity disintegration tablet according to claim 2, the granule after the taste masking Cotton seeds is below 450 μ m.
5, oral cavity disintegration tablet according to claim 1, used filler comprises mannitol, sorbitol, lactose, StarLac
, MicroceLac
, also can be the compositions of above-mentioned each component.
6, oral cavity disintegration tablet according to claim 1, used disintegrating agent comprises the compositions of carboxymethyl starch sodium, cross-linking sodium carboxymethyl cellulose, crospolyvinylpyrrolidone, microcrystalline Cellulose and above-mentioned disintegrating agent.
7, oral cavity disintegration tablet according to claim 1, used correctives comprises aspartame, acesulfame potassium, stevioside.
8, oral cavity disintegration tablet according to claim 1, institute with lubricator comprises PEG6000, boric acid, sodium stearyl fumarate, fumaric acid, magnesium stearate and micropowder silica gel.
9, oral cavity disintegration tablet according to claim 1 is characterized in that slice, thin piece can disintegrate in 5～50 seconds.
10, the preparation method of oral cavity disintegration tablet according to claim 1 is characterized in that may further comprise the steps:
The preparation of active constituents of medicine taste masked particle: take by weighing the active constituents of medicine (can add an amount of correctives) of ormal weight,, after the adding suitable quantity of water is granulated, granule is carried out the taste masking Cotton seeds with Eudragit E 100 dispersions with its mixing.
After active constituents of medicine taste masked particle and all the other auxiliary materials and mixing, add the moderate lubrication agent, tabletting, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100389872A CN100427088C (en) | 2004-05-17 | 2004-05-17 | Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100389872A CN100427088C (en) | 2004-05-17 | 2004-05-17 | Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1698607A true CN1698607A (en) | 2005-11-23 |
| CN100427088C CN100427088C (en) | 2008-10-22 |
Family
ID=35474958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100389872A Expired - Fee Related CN100427088C (en) | 2004-05-17 | 2004-05-17 | Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100427088C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100358523C (en) * | 2006-01-24 | 2008-01-02 | 杭州民生药业集团有限公司 | Preparation method of paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral disintegration tablet |
| CN105982859A (en) * | 2015-01-29 | 2016-10-05 | 北京科信必成医药科技发展有限公司 | Acetaminophen granule with odor masked and preparation method of same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1476898A (en) * | 2002-08-23 | 2004-02-25 | 涛 吴 | Compound skeleton tablet capable of prolonging release after oral administrationi for curing common cold |
-
2004
- 2004-05-17 CN CNB2004100389872A patent/CN100427088C/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100358523C (en) * | 2006-01-24 | 2008-01-02 | 杭州民生药业集团有限公司 | Preparation method of paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral disintegration tablet |
| CN105982859A (en) * | 2015-01-29 | 2016-10-05 | 北京科信必成医药科技发展有限公司 | Acetaminophen granule with odor masked and preparation method of same |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100427088C (en) | 2008-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1976562B1 (en) | Water-soluble films comprising low-viscosity alginates | |
| TWI254640B (en) | Use of a polymer of acrylic type as a disintegration agent | |
| JP4365106B2 (en) | Pharmaceutical combination | |
| JPWO2002096406A1 (en) | Pharmaceutical composition | |
| KR20050120753A (en) | Transmucosal drug delivery system | |
| SE453797B (en) | THERAPEUTIC, SOLID UNIT DOSAGE FORM WITH EXTENDED DISPOSAL SAMPLES WHERE BERARM MATERIALS INCLUDE HYDROXYPROPYLMETHYL CELLULOSA WITH HIGH MOLECULES WEIGHT | |
| CN101073563B (en) | Chiral composition containing dextrothyroxine buprofenli and levomethadyl cysteliqin and its double slow-releasing tablet | |
| CN106727271A (en) | Small-volume oral transmucosal dosage forms | |
| US20160120802A1 (en) | Orally-disintegrating oseltamivir tablet and method for preparing the same | |
| JP2007517011A (en) | Multiparticulate formulation for oral delivery | |
| JP5208729B2 (en) | Method for producing sustained-release tablets | |
| JP2007131561A (en) | Oral solid preparation and method for producing the same | |
| JP2007119453A (en) | Method for preventing lowering of bromhexine hydrochloride content | |
| CN1698607A (en) | Paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral cavity disintegration tablet for treating cold and preparation method thereof | |
| CN1771915A (en) | Oral disintegrated Anfenmame tablet for treating children's cold and its prepn | |
| TWI468189B (en) | Oral internal disintegrating tablet and its manufacturing method | |
| JP6140570B2 (en) | Ibuprofen-containing tablet and method for producing the same | |
| AU2012238330B1 (en) | Fast Dissolving Solid Dosage Form | |
| CN111228227A (en) | Salbutamol sulfate oral disintegrating tablet and preparation method thereof | |
| CN103585125B (en) | Camostat mesilate orally disintegrating tablet, and preparation method and new application thereof | |
| CN102380101B (en) | Pholcodine-containing compound pharmaceutical preparation for treating cold | |
| CN1931168A (en) | Oral disintegrated difenidol hydrochloride tablet and its prepn process | |
| CN109806233B (en) | Composition containing flupirtine or medicinal salt thereof and preparation method thereof | |
| CN116919907A (en) | Rumepirone orally disintegrating tablet and preparation method thereof | |
| CN100358523C (en) | Preparation method of paracetamol pseudoephedrine hydrochloride and cholrphenamine maleate oral disintegration tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: HANGZHOU MINSHENG MEDCINE CO., LTD. Free format text: FORMER NAME: HANGZHOU MINSHENG PHARMACEUTICAL GROUP CO. |
|
| CP03 | Change of name, title or address |
Address after: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee after: Hangzhou Minsheng Pharmaceutical Co., Ltd. Address before: No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee before: Hangzhou Minsheng Pharmaceutical Group Co., Ltd. |
|
| ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU RENHENG PHARMACEUTICAL TECHNOLOGY CO., L Free format text: FORMER OWNER: HANGZHOU MINSHENG PHARMACEUTICAL CO., LTD. Effective date: 20150528 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 310011 HANGZHOU, ZHEJIANG PROVINCE TO: 510305 GUANGZHOU, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20150528 Address after: 510305 west side of the third floor of A4 building, 171 Haizhuqu District Road, Guangdong, Guangzhou Patentee after: Guangzhou Ren Heng Pharmaceutical Technology Co., Ltd Address before: 310011 No. 108 Tong Road, Hangzhou, Zhejiang, Yuhang Patentee before: Hangzhou Minsheng Pharmaceutical Co., Ltd. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081022 Termination date: 20160517 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |